These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24634204)

  • 1. Updating the OMERACT filter: core areas as a basis for defining core outcome sets.
    Kirwan JR; Boers M; Hewlett S; Beaton D; Bingham CO; Choy E; Conaghan PG; D'Agostino MA; Dougados M; Furst DE; Guillemin F; Gossec L; van der Heijde DM; Kloppenburg M; Kvien TK; Landewé RB; Mackie SL; Matteson EL; Mease PJ; Merkel PA; Ostergaard M; Saketkoo LA; Simon L; Singh JA; Strand V; Tugwell P
    J Rheumatol; 2014 May; 41(5):994-9. PubMed ID: 24634204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity.
    Tugwell P; Boers M; D'Agostino MA; Beaton D; Boonen A; Bingham CO; Choy E; Conaghan PG; Dougados M; Duarte C; Furst DE; Guillemin F; Gossec L; Heiberg T; van der Heijde DM; Hewlett S; Kirwan JR; Kvien TK; Landewé RB; Mease PJ; Østergaard M; Simon L; Singh JA; Strand V; Wells G
    J Rheumatol; 2014 May; 41(5):1000-4. PubMed ID: 24692531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.
    Boers M; Kirwan JR; Gossec L; Conaghan PG; D'Agostino MA; Bingham CO; Brooks PM; Landewé R; March L; Simon L; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2014 May; 41(5):1025-30. PubMed ID: 24584913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updating the OMERACT filter: implications for imaging and soluble biomarkers.
    D'Agostino MA; Boers M; Kirwan J; van der Heijde D; Østergaard M; Schett G; Landewé RB; Maksymowych WP; Naredo E; Dougados M; Iagnocco A; Bingham CO; Brooks PM; Beaton DE; Gandjbakhch F; Gossec L; Guillemin F; Hewlett SE; Kloppenburg M; March L; Mease PJ; Moller I; Simon LS; Singh JA; Strand V; Wakefield RJ; Wells GA; Tugwell P; Conaghan PG
    J Rheumatol; 2014 May; 41(5):1016-24. PubMed ID: 24584916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward a generalized framework of core measurement areas in clinical trials: a position paper for OMERACT 11.
    Boers M; Idzerda L; Kirwan JR; Beaton D; Escorpizo R; Boonen A; Magasi S; Sinha I; Stucki G; Tugwell P
    J Rheumatol; 2014 May; 41(5):978-85. PubMed ID: 24584922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updating the OMERACT filter at OMERACT 11.
    Kirwan JR; Boers M; Tugwell P
    J Rheumatol; 2014 May; 41(5):975-7. PubMed ID: 24788466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updating the OMERACT filter: discrimination and feasibility.
    Wells G; Beaton DE; Tugwell P; Boers M; Kirwan JR; Bingham CO; Boonen A; Brooks P; Conaghan PG; D'Agostino MA; Dougados M; Furst DE; Gossec L; Guillemin F; Helliwell P; Hewlett S; Kvien TK; Landewé RB; March L; Mease PJ; Ostergaard M; Simon L; Singh JA; Strand V; van der Heijde DM
    J Rheumatol; 2014 May; 41(5):1005-10. PubMed ID: 24692522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updating the OMERACT filter: implications for patient-reported outcomes.
    Kirwan JR; Bartlett SJ; Beaton DE; Boers M; Bosworth A; Brooks PM; Choy E; de Wit M; Guillemin F; Hewlett S; Kvien TK; Landewé RB; Leong AL; Lyddiatt A; March L; May J; Montie PL; Nikaï E; Richards P; Voshaar MM; Smeets W; Strand V; Tugwell P; Gossec L
    J Rheumatol; 2014 May; 41(5):1011-5. PubMed ID: 24584919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0.
    Boers M; Kirwan JR; Wells G; Beaton D; Gossec L; d'Agostino MA; Conaghan PG; Bingham CO; Brooks P; Landewé R; March L; Simon LS; Singh JA; Strand V; Tugwell P
    J Clin Epidemiol; 2014 Jul; 67(7):745-53. PubMed ID: 24582946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we decide which outcomes should be measured in every clinical trial? A scoping review of the existing conceptual frameworks and processes to develop core outcome sets.
    Idzerda L; Rader T; Tugwell P; Boers M
    J Rheumatol; 2014 May; 41(5):986-93. PubMed ID: 24584917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies.
    Boers M; Beaton DE; Shea BJ; Maxwell LJ; Bartlett SJ; Bingham CO; Conaghan PG; D'Agostino MA; de Wit MP; Gossec L; March L; Simon LS; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2019 Aug; 46(8):1021-1027. PubMed ID: 30770515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting.
    Toupin-April K; Barton J; Fraenkel L; Li LC; Brooks P; De Wit M; Stacey D; Légaré F; Meara A; Shea B; Lyddiatt A; Hofstetter C; Gossec L; Christensen R; Scholte-Voshaar M; Suarez-Almazor ME; Boonen A; Meade T; March L; Pohl C; Jull JE; Sivarajah S; Campbell W; Alten R; Karuranga S; Morgan E; Kaufman J; Hill S; Maxwell LJ; Welch V; Beaton D; El-Miedany Y; Tugwell PS
    J Rheumatol; 2017 Oct; 44(10):1544-1550. PubMed ID: 28765239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.
    Maxwell LJ; Beaton DE; Shea BJ; Wells GA; Boers M; Grosskleg S; Bingham CO; Conaghan PG; D'Agostino MA; de Wit M; Gossec L; March L; Simon LS; Singh JA; Strand V; Tugwell P
    J Rheumatol; 2019 Aug; 46(8):1014-1020. PubMed ID: 30770502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.
    Klokker L; Tugwell P; Furst DE; Devoe D; Williamson P; Terwee CB; Suarez-Almazor ME; Strand V; Woodworth T; Leong AL; Goel N; Boers M; Brooks PM; Simon LS; Christensen R
    J Rheumatol; 2017 Dec; 44(12):1916-1919. PubMed ID: 27744393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets.
    Tunis SR; Maxwell LJ; Graham ID; Shea BJ; Beaton DE; Bingham CO; Brooks P; Conaghan PG; D'Agostino MA; de Wit MP; Gossec L; March LM; Simon LS; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2017 Oct; 44(10):1551-1559. PubMed ID: 28765256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OMERACT: an international initiative to improve outcome measurement in rheumatology.
    Boers M; Brooks P; Simon LS; Strand V; Tugwell P
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S10-3. PubMed ID: 16273779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.
    Beaton DE; Maxwell LJ; Shea BJ; Wells GA; Boers M; Grosskleg S; Bingham CO; Conaghan PG; D'Agostino MA; de Wit MP; Gossec L; March LM; Simon LS; Singh JA; Strand V; Tugwell P
    J Rheumatol; 2019 Aug; 46(8):1028-1035. PubMed ID: 30709952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group.
    Cai K; Fuller A; Zhang Y; Hensey O; Grossberg D; Christensen R; Shea B; Singh JA; McCarthy GM; Rosenthal AK; Filippou G; Taylor WJ; Diaz-Torne C; Stamp LK; Edwards NL; Pascart T; Becce F; Nielsen SM; Tugwell P; Beaton D; Abhishek A; Tedeschi SK; Dalbeth N
    Semin Arthritis Rheum; 2021 Aug; 51(4):946-950. PubMed ID: 34140183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol.
    Kelly A; Tong A; Tymms K; March L; Craig JC; De Vera M; Evans V; Hassett G; Toupin-April K; van den Bemt B; Teixeira-Pinto A; Alten R; Bartlett SJ; Campbell W; Dawson T; Gill M; Hebing R; Meara A; Nieuwlaat R; Shaw Y; Singh JA; Suarez-Almazor M; Sumpton D; Wong P; Christensen R; Beaton D; de Wit M; Tugwell P;
    Trials; 2018 Mar; 19(1):204. PubMed ID: 29587864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.
    Orbai AM; Holland R; Leung YY; Tillett W; Goel N; Christensen R; McHugh N; Gossec L; de Wit M; Højgaard P; Coates LC; Mease PJ; Birt J; Fallon L; FitzGerald O; Ogdie A; Shea B; Strand V; Duffin KC; Tugwell P; Beaton D; Gladman DD
    J Rheumatol; 2019 Aug; 46(8):990-995. PubMed ID: 30554154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.